Neoprobe starts second Lymphoseek trial

Gamma camera probe developer Neoprobe of Dublin, OH, has begun enrollment for a second multicenter phase III trial for its Lymphoseek radiopharmaceutical agent.

The study will evaluate the efficacy of Lymphoseek in identifying sentinel lymph nodes that may predict whether a patient's cancer has spread into the lymphatic system. The trial will include 60 patients with lymph node disease, according to Neoprobe.

Related Reading

Neoprobe hits Lymphoseek clinical milestone, March 19, 2009

Neoprobe debuts high-energy probe, March 5, 2009

Neoprobe taps new VP, February 10, 2009

Neoprobe completes financing, December 8, 2008

Neoprobe gets OK for Lymphoseek study, April 16, 2008

Copyright © 2009 AuntMinnie.com

Page 1 of 435
Next Page